PoC Study to Evaluate the Efficacy and Safety of Secukinumab 300 mg in Patients With Lichen Planus

Condition:   Lichen Planus: Cutaneous Lichen Planus, Mucosal Lichen Planus and Lichen Planopilaris Interventions:   Drug: Cutaneous lichen planus secukinumab 300 mg Q4W;   Drug: Cutaneous lichen planus placebo;   Drug: Mucosal lichen planus placebo;   Drug: Lichen planopilaris placebo;   Drug: Mucosal lichen planus secukinumab 300 mg Q4W;   Drug: Lichen planopilaris secukinumab 300 mg Q4 W Sponsor:   Novartis Pharmaceuticals Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials